Viewing Study NCT02532257

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:47 PM
Ignite Modification Date: 2026-03-04 @ 8:46 PM
Study NCT ID: NCT02532257
Status: COMPLETED
Last Update Posted: 2024-09-24
First Post: 2015-08-21
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma
Sponsor: M.D. Anderson Cancer Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Ann Arbor Stage II Follicular Lymphoma View
None Ann Arbor Stage II Marginal Zone Lymphoma View
None Ann Arbor Stage III Follicular Lymphoma View
None Ann Arbor Stage III Marginal Zone Lymphoma View
None Ann Arbor Stage IV Follicular Lymphoma View
None Ann Arbor Stage IV Marginal Zone Lymphoma View
None CD20 Positive View
None Grade 1 Follicular Lymphoma View
None Grade 2 Follicular Lymphoma View
None Grade 3a Follicular Lymphoma View
Keywords: